Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: Preliminary results

Ohguri, Takayuki; Imada, Hajime; Narisada, Hiroyuki; Yahara, Katsuya; Morioka, Tomoaki; Nakano, Kazushi; Miyaguni, Yasuhiro; Korogi, Yukunori

doi:10.1080/02656730802610357

Cited by 47 publications

(40 citation statements)

References 33 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…The Thermotron RF-8 is a capacitive heating device operating at 8 MHz, in which the patient is placed between two electrodes connected to a high-power RF generator, and the use of this device has been reported previously [11][12][13]. In 23 of 33 patients, both the upper and lower electrodes were 30 cm in diameter, placed on opposite sides of the thoracic region, in 3 patients, both the upper and lower electrodes were 25 cm, in 4 patients, the upper electrode was 25 cm and lower was 30 cm, and in 3 patients, the upper electrode was 10 cm and the lower was 30 cm.…”

Section: Hyperthermiamentioning

confidence: 99%

Re-irradiation plus regional hyperthermia for recurrent non-small cell lung cancer: A potential modality for inducing long-term survival in selected patients

et al. 2012

Self Cite

View full text Add to dashboard Cite

Section: Hyperthermiamentioning

confidence: 99%

Re-irradiation plus regional hyperthermia for recurrent non-small cell lung cancer: A potential modality for inducing long-term survival in selected patients

et al. 2012

Self Cite

View full text Add to dashboard Cite

“…Moreover, clinical studies in patients with gliomas 160 and NSCLC (ref. 161 ) have shown promising results, and several studies with the combination of HBOT and radiotherapy have been also performed 162 . However, this approach is still in its infancy and a number of questions, e.g.…”

Section: Future Perspectivesmentioning

confidence: 99%

Hypoxia-induced chemoresistance in cancer cells: The role of not only HIF-1

Doktorova

Hraběta

Khalil

et al. 2015

Biomed Pap Med Fac Univ Palacky Olomouc Czech Repub

View full text Add to dashboard Cite

Background. The aim of this review is to provide the information about molecular basis of hypoxia-induced chemoresistance, focusing on the possibility of diagnostic and therapeutic use. Results. Hypoxia is a common feature of tumors and represents an independent prognostic factor in many cancers. It is the result of imbalances in the intake and consumption of oxygen caused by abnormal vessels in the tumor and the rapid proliferation of cancer cells. Hypoxia-induced resistance to cisplatin, doxorubicin, etoposide, melphalan, 5-flouoruracil, gemcitabine, and docetaxel has been reported in a number of experiments. Adaptation of tumor cells to hypoxia has important biological effects. The most studied factor responsible for these effects is hypoxia-inducible factor-1 (HIF-1) that significantly contributes to the aggressiveness and chemoresistance of different tumors. The HIF-1 complex, induced by hypoxia, binds to target genes, thereby increasing the expression of many genes. In addition, the expression of hundreds of genes can be also decreased in response to hypoxia in HIF-1 dependent manner, but without the detection of HIF-1 in these genes' promoters. HIF-1 independent mechanisms for drug resistance in hypoxia have been described, however, they are still rarely reported. The first clinical studies focusing on diagnosis of hypoxia and on inhibition of hypoxia-induced changes in cancer cells are starting to yield results. Conclusions. The adaptation to hypoxia requires many genetic and biochemical responses that regulate one another. Hypoxia-induced resistance is a very complex field and we still know very little about it. Different approaches to circumvent hypoxia in tumors are under development.

show abstract

“…By altering the pharmacokinetic parameters and increasing the regional blood flow of tumors, thermotherapy may enhance the cytotoxicity and improve the therapeutic response to anticancer drugs. Other evidence suggests that thermotherapy may help inhibit DNA repair by regulating the DNA polymerase; furthermore, the synthesis and secretion of vascular endothelial growth factor is restrained and the formation of new blood vessels is effectively reduced (9,10). In addition, thermotherapy may enhance the cytotoxic effect of irradiation on S-phase cells and alleviate the toxicity reaction of normal tissue in selected cases (11).…”

Section: Discussionmentioning

confidence: 96%

Optimized treatment with RF thermotherapy and immunotherapy combined with CyberKnife for advanced high-risk tumors: A clinical trial report

et al. 2014

View full text Add to dashboard Cite

This study was conducted to evaluate the application value of optimized treatment with radiofrequency (RF) thermotherapy and immunotherapy combined with CyberKnife for advanced high-risk tumors. The database of 1,013 patients with 2,136 tumor lesions and 1,237 target areas who underwent treatment with CyberKnife between November, 2010 and November, 2012, was retrospectively reviewed. We randomly assigned 505 eligible patients (observation group) to RF thermotherapy and adoptive immunotherapy with cytokine-induced killer cells and the remaining 508 patients (control group) to no adjuvant treatment. The patients in the two groups were recorded on efficacy assessment according to imageological examination, World Health Organization criteria, Karnofsky performance status, or radioimmunoassay (RIA) detection. The effective rate of the observation group was 75.05%, whereas that of the control group was 58.06% (P<0.05). The results revealed that CyberKnife combined with hyperthermia and biological therapy are highly effective in improving the local tumor control rate. Further analysis of the Karnofsky score and RIA detection confirmed that this type of combination therapy significantly improved the quality of life. The optimized treatment of RF thermotherapy and immunotherapy combined with CyberKnife may act synergistically in eliminating tumor cells, confirming the efficacy of this type of treatment for patients with advanced malignant tumors.

show abstract

Systemic chemotherapy using paclitaxel and carboplatin plus regional hyperthermia and hyperbaric oxygen treatment for non-small cell lung cancer with multiple pulmonary metastases: Preliminary results

Abstract: The novel combined therapy of paclitaxel and carboplatin with HT and HBO may therefore be a feasible and promising modality for treating NSCLC with multiple pulmonary metastases, and the results justify further evaluation to clarify the benefits of this treatment regimen.

Cited by 47 publications

References 33 publications

Re-irradiation plus regional hyperthermia for recurrent non-small cell lung cancer: A potential modality for inducing long-term survival in selected patients

Re-irradiation plus regional hyperthermia for recurrent non-small cell lung cancer: A potential modality for inducing long-term survival in selected patients

Hypoxia-induced chemoresistance in cancer cells: The role of not only HIF-1

Optimized treatment with RF thermotherapy and immunotherapy combined with CyberKnife for advanced high-risk tumors: A clinical trial report

Contact Info

Product

Resources

About